Navigation Links
Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
Date:5/5/2008

Presentation Scheduled for Wednesday, May 7th at 9:30am EDT

NEW YORK, May 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 33rd Annual Health Care Conference in Boston, Massachusetts.

Mr. Weiss' presentation, which will take place on Wednesday, May 7th at 9:30am EDT, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell surviva
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Receives Nasdaq Notification
2. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
7. Keryx Biopharmaceuticals Announces Additions to Management Team
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Micro...y that it has re-filed the Form 52-109F1 Certifica...f Executive Officer and James Long, the Chief Fina... January 12, 2009 in connection with the annual au...ember 30, 2008. ,, The Company initially filed ...
(Date:11/6/2009)..., VIENNA, Austria, November 6 /PRNewswire/ -...izing, manufacturing, and marketing enzymes for th...tered into a research,agreement with Bio Sidus, th...ca. , The agreement gives EUCODIS Bioscie...f interest - to Bio Sidus, proprietary collection ...
(Date:11/6/2009)..., HAYWARD, Calif., Nov. 6 Intarc...today on its ITCA 650 (DUROS® continuous deli...pe 2 diabetes at the Ninth Annual Diabetes Technol...tp://www.newscom.com/cgi-bin/prnh/20050301/SFTU126... Exenatide Via ITCA 650 Lowers Plasma Glucose, HbA...
(Date:11/5/2009)..., WELLINGTON, Colo., Nov. 5 The ...g towns in the western U.S. This rare carnivore f...susceptible to plague and often entire population ...life Service (FWS) has implemented a ferret breedi... ferrets into their formerly native habitat. Unfo...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
...-Plough Corporation (NYSE: SGP ) will provide a ...olson, Ph.D., senior vice president, Global Projec...search Institute, at the Barclays Capital Global H..., at approximately 2 p.m. EDT. Nicholson is expec...nd select projects in development. , , A live aud...
...nounced , , Ergonomics Programs Prove Vital in ...h Annual National Ergonomics Conference and Exposi...gas, November 17 - 20, 2009. As of today, nearly ...bitors have already renewed. , , Exhibitors, in...r AliMed, are already anticipating the show saying...
...ia announces the launch of a suite of miRNA functi...miExpress(TM) vector based precursor miRNA express...(3, UTR) expression clones; and 3) All-in-One(TM) ...iral vector system, miExpress(TM) precursor miRNA...NAs for human (750), mouse (450), and rat (270). T...
Other Biology Technology:National Ergonomics Conference and Expo Reaches 94% Exhibitor Renewal Rate 2GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools 2
(Date:11/9/2009)...may be more than twice as likely to develop multip...ns who are not obese, according to a study publish...logy , the medical journal of the American Academy...omen from the Nurses, Health Study and Nurses, Hea...n answered a questionnaire about their health beha...
(Date:11/9/2009)...wire/ -- CBS Vision, the research division of CBS ...a Group company, today announced a new research pa...the CBS Television City research facility housed i... venture, which marries the capabilities of CBS Vi...ll be called Communications Lab@OMD . ,, CBS,s...
(Date:11/9/2009)...nia and elsewhere provide support for the use of m...d protecting marine habitats, according to biologi..., A recent study in the Gulf of California, for ...ehind marine reserves--the idea that offspring pro... of harvested species outside the reserve. , "It...
Breaking Biology News(10 mins):Teenage obesity linked to increased risk of MS 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4Studies show marine reserves can be an effective tool for managing fisheries 2Studies show marine reserves can be an effective tool for managing fisheries 3Studies show marine reserves can be an effective tool for managing fisheries 4Studies show marine reserves can be an effective tool for managing fisheries 5NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 59451 1NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 59451 2NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 59451 3Sundia Welcomes Professional U S Delegation 14469 1Sundia Welcomes Professional U S Delegation 14469 2Increased success a virtual certainty for rugby players 59448 1Increased success a virtual certainty for rugby players 59448 2
...eople with high cholesterol in their early 40s are...hose with low cholesterol, according to research t...demy of Neurology 60th Anniversary Annual Meeting ...w it would be best for both physicians and patient...o reduce the risk of dementia," said study author ...
...industry has long touted antioxidants as a way to ...ew review of studies found no evidence that the nu... authors said that some antioxidants could increas...ation of the nutraceuticals industry, but an antio...culture said that call for stricter monitoring ove...
... Fla. University of Florida researchers have iden...who appear especially vulnerable to the physical e...flow to the heart is greatly reduced. , Searching...etter identify patients who are at an increased ri...a professor and associate chairman of cardiovascul...
Other Biology News:Antioxidant users don't live longer, analysis of studies concludes 2Antioxidant users don't live longer, analysis of studies concludes 3Mental stress reduces blood flow to the heart in patients with gene variation 2Mental stress reduces blood flow to the heart in patients with gene variation 3
Mouse/Rat Anti-Canine CD3 / CD4 Dual Colour Reagent Antibody, FITC / R-Phycoerythrin Conjugated from AbD Serotec
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) *FluoroPure™ grade* from Molecular Probes (Invitrogen)
Essential Techniques: Gel Electrophoresis: Proteins from Promega
Colloids and Interfaces with Surfactants and Polymers an Introduction. Jim Goodwin. Wiley (2004); 296 pages soft cover from Invitrogen
Biology Products: